Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
Similar Posts
Iran as the Political Winner: The Preliminary Ceasefire with the USA
The two-week ceasefire agreed upon on Tuesday between the USA, Israel, and Iran marks the preliminary end of an escalation that has gripped the Middle East since February 2026.
Government Failure in Winter Services – Germany in Snow Chaos 2026
A winter storm with up to 15 centimeters of new snow has plunged Germany into traffic chaos. Highways and country roads are blocked in many places, accidents are increasing, and the…
Dementia: Recognizing Symptoms and Warning Signs
Dementia is a progressive brain disease that leads to a decline in cognitive abilities. It affects memory, thinking, orientation, and the…
